Media headlines about Ascendis Pharma A/S (NASDAQ:ASND) have trended positive on Monday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ascendis Pharma A/S earned a media sentiment score of 0.28 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.8796109280509 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- What analyst predict for Ascendis Pharma NASDAQ:ASND ? (stockmarketdaily.co)
- JPMorgan Chase & Co. Raises Ascendis Pharma A/S (ASND) Price Target to $75.00 (americanbankingnews.com)
- Ascendis Pharma (ASND) PT Raised to $75 at JPMorgan; ‘Pipeline Updates Increase Our Confidence’ (streetinsider.com)
- Ascendis Pharma A/S (ASND) Set to Announce Earnings on Wednesday (americanbankingnews.com)
- Ascendis Pharma A/S’s (ASND) Hold Rating Reaffirmed at Credit Suisse Group (americanbankingnews.com)
Ascendis Pharma A/S (NASDAQ:ASND) opened at $64.32 on Monday. The firm has a market capitalization of $2,670.82, a P/E ratio of -17.67 and a beta of 0.68. Ascendis Pharma A/S has a 12-month low of $21.95 and a 12-month high of $69.00.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.